HALO241220C50000
- 1.25
- +0.30+31.58%
Halozyme Therapeutics Newsroom
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
Halozyme to Present at Upcoming Investor Conferences
HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up
Halozyme Therapeutics Price Target Maintained With a $68.00/Share by HC Wainwright & Co.
Evotec Refutes Halozyme Therapeutics' Reason for Buyout Bid Withdrawal
Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet
Trending: Halozyme Drops Bid for Evotec
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's Why
Express News | Evotec Confirms Review Of Halozyme's Withdrawn EUR 11.00/Share Proposal, Reiterates Confidence In Standalone Growth Strategy
Express News | U.S.-Listed Shares of Evotec Down 19.8% Premarket
Sector Update: Health Care Stocks Advance Premarket Friday
Sector Update: Health Care
Halozyme Therapeutics Shares Are Trading Higher After the Company Announced It Withdrew Plans to Acquire Evotec.
Halozyme Therapeutics Well-positioned to Execute Existing Strategy With Clear Line of Sight to 10 Approved Products With ENHANZE in 2025 and $1B of Royalty Rev in 2027 >HALO
Express News | Halozyme Therapeutics Inc: Reiterate Raised 2024 Guidance for Revenue of $970-$1,020 Mln and Adjusted Ebitda of $595-$625 Mln
Press Release: Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions
Halozyme Therapeutics Analyst Ratings
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $68
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)